Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Sutacimig Phase 2 LTE data indicate sustained bleed reduction, with safety and tolerability described as manageable. The company plans to initiate Phase 3 in 2H 2026, suggesting continued clinical momentum that is modestly supportive for the program and near-term sentiment.

Analysis

Sutacimig Phase 2 LTE data indicate sustained bleed reduction, with safety and tolerability described as manageable. The company plans to initiate Phase 3 in 2H 2026, suggesting continued clinical momentum that is modestly supportive for the program and near-term sentiment.